1. Bio-Modeling Systems (BMS) is a biotech company that creates CADI models to accelerate life sciences research and discoveries for clients.
2. CADI models are detailed maps of inter-cellular and intra-cellular mechanisms associated with biological states that can describe disease processes without using mathematics.
3. BMS generates revenue by applying CADI models to research programs for pharmaceutical, biotech, chemical and other industries, helping to identify new targets, biomarkers, and therapeutic strategies more quickly and at lower cost.
The Expanding eClinical Universe: Streamlining Progress by Changing Current W...crystalhuntergtcbio
The document discusses how clinical trials are moving from paper-based processes to electronic systems to improve efficiency. It highlights trends like increased adoption of electronic data capture systems and clinical trial management systems. The clinical trials IT ecosystem is becoming more interconnected through technologies that provide better data access, analytics, and responsiveness to potential drug safety issues. Vendors are offering more comprehensive eClinical solutions through hosted systems and software-as-a-service models. This transformation aims to streamline work processes and address challenges like rising costs in global clinical trials.
quality of configuration information- how to measure and improve itDick Terleth
This document summarizes a presentation about measuring and improving the quality of configuration information. The presentation discusses how bad configuration data can lead to bad decisions and waste. It emphasizes that quality information is needed to make good decisions. The presentation then discusses using indicators and dashboards to measure different quality dimensions of configuration information, such as accuracy, completeness, and consistency. Examples of indicators for a rail infrastructure project are provided. The presentation concludes that continuously improving information quality requires defining information models, validation rules, measuring indicators, and incorporating experts.
This document discusses challenges in process plant design and chemical engineering. It summarizes a course on process plant design that teaches students to systematically design processes by integrating different disciplines. The course uses over 170 design cases and many are published or presented. Process intensification quick scans are also discussed, which identify opportunities to improve processes. These scans stimulate process innovation by reconsidering daily activities and cross-fertilizing disciplines. Sustainable product and process design is important to address challenges around energy, water, and raw materials to take responsibility.
Team 18 is developing a modular attachment for optical microscopes that uses Quantitative Phase Imaging (QPI) technology to provide faster, cheaper, and more accurate results for cancer and blood disorder research compared to state-of-the-art instrumentation. They have over 100 customers including universities, bio-pharma companies, and OEMs. Key members include experts in noninvasive biomedical imaging and entrepreneurship with experience commercializing start-up technologies.
Cleanergetic SEERS Solutions is an independent consulting firm founded in 2012 providing renewable energy and energy efficiency services. It offers technical assessments, engineering design, and asset management for photovoltaic plant owners. The company aims to expand into energy services and the development of residential and commercial solutions to promote net metering and zero emission building design.
BCPharMed is a life sciences consulting firm founded in 2008 that provides a range of services to pharmaceutical and medical device clients globally. Their methodology focuses on timely delivery, validation of results, and customer satisfaction. They have expertise in areas such as marketing strategy, industrial strategy, outsourcing, product development, manufacturing, and business development. Their competitive advantages include their experienced team, global resources, focus on the life sciences sector, and track record of adding value and enabling successful outcomes for clients.
As businesses search for lower costs, supply chains have evolved from local to regional to global, and are increasing levels for offshoring of component suppliers and contract manufacturers. As a result, new risks associated with Intellectual Property (IP) have been introduced into design and supply chains. Mitigating these risks is essential for the successful commercialization of new products.
Gain 5 valuable insights about:
• IP Leakage and where it typically happens
• Where does it happen?
• Current Supply Chain models
• Key product considerations
• Structural solutions to protect IP
This document provides guidance on creating a content strategy for a business by outlining four key steps: 1) Know your audience by developing buyer personas, 2) Conduct a content audit to identify gaps and opportunities, 3) Map content to the buying cycle to determine the best types of content for each stage, and 4) Create an editorial calendar to plan content creation and publication over multiple months based on goals, buyer personas, and key dates. The editorial calendar approach helps ensure a consistent pipeline of optimized content.
The Expanding eClinical Universe: Streamlining Progress by Changing Current W...crystalhuntergtcbio
The document discusses how clinical trials are moving from paper-based processes to electronic systems to improve efficiency. It highlights trends like increased adoption of electronic data capture systems and clinical trial management systems. The clinical trials IT ecosystem is becoming more interconnected through technologies that provide better data access, analytics, and responsiveness to potential drug safety issues. Vendors are offering more comprehensive eClinical solutions through hosted systems and software-as-a-service models. This transformation aims to streamline work processes and address challenges like rising costs in global clinical trials.
quality of configuration information- how to measure and improve itDick Terleth
This document summarizes a presentation about measuring and improving the quality of configuration information. The presentation discusses how bad configuration data can lead to bad decisions and waste. It emphasizes that quality information is needed to make good decisions. The presentation then discusses using indicators and dashboards to measure different quality dimensions of configuration information, such as accuracy, completeness, and consistency. Examples of indicators for a rail infrastructure project are provided. The presentation concludes that continuously improving information quality requires defining information models, validation rules, measuring indicators, and incorporating experts.
This document discusses challenges in process plant design and chemical engineering. It summarizes a course on process plant design that teaches students to systematically design processes by integrating different disciplines. The course uses over 170 design cases and many are published or presented. Process intensification quick scans are also discussed, which identify opportunities to improve processes. These scans stimulate process innovation by reconsidering daily activities and cross-fertilizing disciplines. Sustainable product and process design is important to address challenges around energy, water, and raw materials to take responsibility.
Team 18 is developing a modular attachment for optical microscopes that uses Quantitative Phase Imaging (QPI) technology to provide faster, cheaper, and more accurate results for cancer and blood disorder research compared to state-of-the-art instrumentation. They have over 100 customers including universities, bio-pharma companies, and OEMs. Key members include experts in noninvasive biomedical imaging and entrepreneurship with experience commercializing start-up technologies.
Cleanergetic SEERS Solutions is an independent consulting firm founded in 2012 providing renewable energy and energy efficiency services. It offers technical assessments, engineering design, and asset management for photovoltaic plant owners. The company aims to expand into energy services and the development of residential and commercial solutions to promote net metering and zero emission building design.
BCPharMed is a life sciences consulting firm founded in 2008 that provides a range of services to pharmaceutical and medical device clients globally. Their methodology focuses on timely delivery, validation of results, and customer satisfaction. They have expertise in areas such as marketing strategy, industrial strategy, outsourcing, product development, manufacturing, and business development. Their competitive advantages include their experienced team, global resources, focus on the life sciences sector, and track record of adding value and enabling successful outcomes for clients.
As businesses search for lower costs, supply chains have evolved from local to regional to global, and are increasing levels for offshoring of component suppliers and contract manufacturers. As a result, new risks associated with Intellectual Property (IP) have been introduced into design and supply chains. Mitigating these risks is essential for the successful commercialization of new products.
Gain 5 valuable insights about:
• IP Leakage and where it typically happens
• Where does it happen?
• Current Supply Chain models
• Key product considerations
• Structural solutions to protect IP
This document provides guidance on creating a content strategy for a business by outlining four key steps: 1) Know your audience by developing buyer personas, 2) Conduct a content audit to identify gaps and opportunities, 3) Map content to the buying cycle to determine the best types of content for each stage, and 4) Create an editorial calendar to plan content creation and publication over multiple months based on goals, buyer personas, and key dates. The editorial calendar approach helps ensure a consistent pipeline of optimized content.
This document discusses Bio-Modeling Systems' (BMS) approach to integrative systems biology modeling called CADI (Computer Assisted Deductive Integration). CADI models are descriptive in-silico models of biological systems and diseases that can explain nonlinear mechanisms and identify new discoveries. The CADI approach applies 5 principles: an architectural approach, a negative selection process, a 4 step validation process, expertise across life sciences and IT, and synergic collaboration. BMS acts as an architect to generate hypotheses that are tested by experimentalists, with the goal of building solid and useful biological models.
Efficient biomolecular structural data handling and analysis - Webinar with D...ChemAxon
In this joint event our experts are coming together to elaborate on the technical and scientific opportunities coming from this partnership. If you are working on the discovery of next generation drugs and using structure-based approach in your research, join us to learn how to leverage vast biomolecular structural data with innovative technologies.
Pistoia presentation bio it-worldexpo 21april2010Nick Lynch
The document summarizes the origins and operations of the Pistoia Alliance, a non-profit organization formed to facilitate pre-competitive collaboration in the life sciences industry. The Pistoia Alliance was formed in Pistoia, Italy by GSK, AZ, Pfizer and Novartis to address common challenges with data interchange. Its mission is to standardize data exchange to reduce costs. Current projects include developing standards for semantic enrichment of literature, sequence data services, and electronic lab notebook queries. The organization has over 30 members and operates working groups to develop open standards through a governance process.
The document discusses the challenges that biopharmaceutical companies face in producing complex biologic drugs at scale. It introduces Bioproduction Group's Real-Time Modeling System software, which uses advanced modeling and links to manufacturing data to help companies understand and optimize their complex biomanufacturing processes. The software accounts for variability, identifies bottlenecks, and allows "what-if" analysis to improve decision-making and maximize production. It has been developed in partnership with large biopharma firms and delivers significant cost savings for its clients.
1) The document discusses boundary spanning leadership and how developing networks can drive collaboration and innovation. It focuses on a case study of the biotech company Merrimack Pharmaceuticals.
2) Merrimack takes a unique multi-disciplinary and team-based approach to drug discovery aimed at more efficiently progressing ideas into novel cancer therapies. It is organized into cross-functional project teams called PODs.
3) A network analysis was conducted to understand how well Merrimack had developed as a networked organization and to identify critical boundaries to collaboration. Several strategies for spanning boundaries like managing, forging common ground, and discovering new frontiers were discussed.
Bhadale group of companies bio technology products catalogueVijayananda Mohire
This is our first version of product offering in areas of Biotechnology using AI and ML for various inference engines and bio engineered devices that enable faster and more accurate predictions
03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10AREA Science Park
Frank Heemskerk presented on research mobility and commercialization. He discussed his background moving between academia and industry research. He emphasized the importance of networking and developing international partnerships between universities, research institutes, SMEs, and other organizations. Recommendations included improving communication between sectors, allowing flexibility in projects, and professionalizing research management to enable collaboration across borders.
Sandor Szalma (Janssen) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session of the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
This document describes the services of a consulting firm called XLR8 that specializes in product development, engineering, manufacturing operations, and quality systems. They have expertise across the entire product lifecycle from new product introductions to operational execution. The firm implements operational transformations for both large and small clients. They work in industries like medical devices, life sciences, cleantech, biotech, semiconductors, and consumer electronics.
Healthcare Information Technology: IBM Health Integration FrameworkIBM HealthCare
Today’s challenges to health plans call for business transformation — the individual member is now the customer. IBM can help make this transition from product model to service model with Health Integration Framework-enabled solutions
This document summarizes a study on improving outcomes in medical device manufacturing. It found that the most successful companies grew more than 10% while improving key metrics like quality and costs. These "advancers" used tools like product lifecycle management (PLM) software to facilitate concurrent, collaborative new product development. PLM helped advancers automate information flows and simulate quality by design, leading to reduced defects and faster time to market. The study concludes that taking a total product lifecycle approach focused on innovation, quality, and information sharing is needed to improve both business performance and patient outcomes.
IBM AI Solutions on Power Systems is a presentation about IBM's AI solutions. It introduces IBM Visual Insights for tasks like image classification, object detection, and segmentation. A use case demo shows breast cancer classification in under one second with high accuracy. Another demo detects diabetic retinopathy in eye images. The presentation discusses open issues in medical imaging AI and IBM's response to COVID-19, including an X-ray demo to detect COVID-19 in lung images. It calls for collaboration to share medical data and models.
1. Bio-Modeling Systems is a French company that uses its proprietary CADITM Discovery platform to generate mechanistic models of diseases and their underlying biological mechanisms.
2. The company was founded in 2004 and has since led collaborations resulting in two therapeutic spin-offs in clinical trials and publications in peer-reviewed journals.
3. CADITM Discovery integrates human and artificial intelligence to address the complexity of biological mechanisms and unreliability of scientific publications in a novel discovery paradigm.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
The document discusses Affinity Therapeutics' technology platform for developing microparticle formulations that provide extended local release of antibiotics to prevent surgical site infections. The company was founded in 2010 and is developing formulations to be used with hernia mesh repairs initially, with the goal of licensing the technology to medical device companies. The company has received an NIH Phase I SBIR grant and is working to negotiate licensing and facility agreements with universities.
An outline of the BioSOlve process cost modelling program how it can be used rapidly evaluate technologies, process options and understand the cost drivers in a process as function of scale etc.
Healthcare and Life Sciences - Cloud ComputingMike Watson
Cloud computing offers healthcare and life sciences companies new opportunities for collaboration, innovation, and efficiency. It allows for vast amounts of data to be securely stored and shared, flexible infrastructure for research needs, and common business processes across organizations. This transforms industries by enabling new models like precision medicine through large-scale analytics and more agile product development through testing and trials in the cloud.
This document summarizes information about biopharma industry competitiveness in France. It discusses France's strengths in the biopharma sector including its ranking as the top region in Europe for pharmaceuticals, medtech, and public-sector research. It profiles the organization Adebiotech which is France's independent multidisciplinary biotechnology think-tank and represents various industrial and academic members. It also summarizes projects from companies in France including Bio-Modeling Systems, Pherecydes Pharma, Clean Cells, and their roles in developing novel therapies, conducting clinical trials, and manufacturing biopharmaceutical products.
This document discusses Bio-Modeling Systems' (BMS) approach to integrative systems biology modeling called CADI (Computer Assisted Deductive Integration). CADI models are descriptive in-silico models of biological systems and diseases that can explain nonlinear mechanisms and identify new discoveries. The CADI approach applies 5 principles: an architectural approach, a negative selection process, a 4 step validation process, expertise across life sciences and IT, and synergic collaboration. BMS acts as an architect to generate hypotheses that are tested by experimentalists, with the goal of building solid and useful biological models.
Efficient biomolecular structural data handling and analysis - Webinar with D...ChemAxon
In this joint event our experts are coming together to elaborate on the technical and scientific opportunities coming from this partnership. If you are working on the discovery of next generation drugs and using structure-based approach in your research, join us to learn how to leverage vast biomolecular structural data with innovative technologies.
Pistoia presentation bio it-worldexpo 21april2010Nick Lynch
The document summarizes the origins and operations of the Pistoia Alliance, a non-profit organization formed to facilitate pre-competitive collaboration in the life sciences industry. The Pistoia Alliance was formed in Pistoia, Italy by GSK, AZ, Pfizer and Novartis to address common challenges with data interchange. Its mission is to standardize data exchange to reduce costs. Current projects include developing standards for semantic enrichment of literature, sequence data services, and electronic lab notebook queries. The organization has over 30 members and operates working groups to develop open standards through a governance process.
The document discusses the challenges that biopharmaceutical companies face in producing complex biologic drugs at scale. It introduces Bioproduction Group's Real-Time Modeling System software, which uses advanced modeling and links to manufacturing data to help companies understand and optimize their complex biomanufacturing processes. The software accounts for variability, identifies bottlenecks, and allows "what-if" analysis to improve decision-making and maximize production. It has been developed in partnership with large biopharma firms and delivers significant cost savings for its clients.
1) The document discusses boundary spanning leadership and how developing networks can drive collaboration and innovation. It focuses on a case study of the biotech company Merrimack Pharmaceuticals.
2) Merrimack takes a unique multi-disciplinary and team-based approach to drug discovery aimed at more efficiently progressing ideas into novel cancer therapies. It is organized into cross-functional project teams called PODs.
3) A network analysis was conducted to understand how well Merrimack had developed as a networked organization and to identify critical boundaries to collaboration. Several strategies for spanning boundaries like managing, forging common ground, and discovering new frontiers were discussed.
Bhadale group of companies bio technology products catalogueVijayananda Mohire
This is our first version of product offering in areas of Biotechnology using AI and ML for various inference engines and bio engineered devices that enable faster and more accurate predictions
03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10AREA Science Park
Frank Heemskerk presented on research mobility and commercialization. He discussed his background moving between academia and industry research. He emphasized the importance of networking and developing international partnerships between universities, research institutes, SMEs, and other organizations. Recommendations included improving communication between sectors, allowing flexibility in projects, and professionalizing research management to enable collaboration across borders.
Sandor Szalma (Janssen) gives an overview of this potential Pistoia Alliance working group during the "Dragons' Den" session of the Pistoia Alliance Conference in Boston, MA, on April 24, 2012.
This document describes the services of a consulting firm called XLR8 that specializes in product development, engineering, manufacturing operations, and quality systems. They have expertise across the entire product lifecycle from new product introductions to operational execution. The firm implements operational transformations for both large and small clients. They work in industries like medical devices, life sciences, cleantech, biotech, semiconductors, and consumer electronics.
Healthcare Information Technology: IBM Health Integration FrameworkIBM HealthCare
Today’s challenges to health plans call for business transformation — the individual member is now the customer. IBM can help make this transition from product model to service model with Health Integration Framework-enabled solutions
This document summarizes a study on improving outcomes in medical device manufacturing. It found that the most successful companies grew more than 10% while improving key metrics like quality and costs. These "advancers" used tools like product lifecycle management (PLM) software to facilitate concurrent, collaborative new product development. PLM helped advancers automate information flows and simulate quality by design, leading to reduced defects and faster time to market. The study concludes that taking a total product lifecycle approach focused on innovation, quality, and information sharing is needed to improve both business performance and patient outcomes.
IBM AI Solutions on Power Systems is a presentation about IBM's AI solutions. It introduces IBM Visual Insights for tasks like image classification, object detection, and segmentation. A use case demo shows breast cancer classification in under one second with high accuracy. Another demo detects diabetic retinopathy in eye images. The presentation discusses open issues in medical imaging AI and IBM's response to COVID-19, including an X-ray demo to detect COVID-19 in lung images. It calls for collaboration to share medical data and models.
1. Bio-Modeling Systems is a French company that uses its proprietary CADITM Discovery platform to generate mechanistic models of diseases and their underlying biological mechanisms.
2. The company was founded in 2004 and has since led collaborations resulting in two therapeutic spin-offs in clinical trials and publications in peer-reviewed journals.
3. CADITM Discovery integrates human and artificial intelligence to address the complexity of biological mechanisms and unreliability of scientific publications in a novel discovery paradigm.
Pfizer Canada is exploring public-private partnerships and open innovation models to address gaps in drug innovation. These models include pre-competitive research partnerships and consortia involving multiple companies, universities, and research institutions. They aim to leverage diverse scientific capabilities and resources to make progress on understanding disease biology and developing new treatments. By sharing knowledge and resources in a pre-competitive space, these partnerships seek to accelerate innovation for the benefit of patients while also engaging industry, academia and government.
Will Biosimilars Be A Driver For InnovationAjaz Hussain
The Biosimilar debate touches upon several important reasons for innovation failure in a regulated environment – successful, scientific, resolution will be important for the entire sector.
The document discusses Affinity Therapeutics' technology platform for developing microparticle formulations that provide extended local release of antibiotics to prevent surgical site infections. The company was founded in 2010 and is developing formulations to be used with hernia mesh repairs initially, with the goal of licensing the technology to medical device companies. The company has received an NIH Phase I SBIR grant and is working to negotiate licensing and facility agreements with universities.
An outline of the BioSOlve process cost modelling program how it can be used rapidly evaluate technologies, process options and understand the cost drivers in a process as function of scale etc.
Healthcare and Life Sciences - Cloud ComputingMike Watson
Cloud computing offers healthcare and life sciences companies new opportunities for collaboration, innovation, and efficiency. It allows for vast amounts of data to be securely stored and shared, flexible infrastructure for research needs, and common business processes across organizations. This transforms industries by enabling new models like precision medicine through large-scale analytics and more agile product development through testing and trials in the cloud.
Similar to Bm Systems Presentation Short 30112009 (20)
This document summarizes information about biopharma industry competitiveness in France. It discusses France's strengths in the biopharma sector including its ranking as the top region in Europe for pharmaceuticals, medtech, and public-sector research. It profiles the organization Adebiotech which is France's independent multidisciplinary biotechnology think-tank and represents various industrial and academic members. It also summarizes projects from companies in France including Bio-Modeling Systems, Pherecydes Pharma, Clean Cells, and their roles in developing novel therapies, conducting clinical trials, and manufacturing biopharmaceutical products.
This document provides information about Bio-Modeling Systems SAS, including contact details and an overview of their services. It discusses the need to change the drug discovery paradigm to address issues like high failure rates and unreliable research. Bio-Modeling Systems provides a platform called CADITM Discovery that uses a mechanisms-based approach and principles like negative selection to model biological complexity and address uncertainties in scientific data. The goal is to improve medical research and validation processes to enhance patient health outcomes.
Andrew Lloyd & Associates, an international PR group, has partnered with Adebiotech, a French think-tank for biotechnology, to promote interdisciplinary innovation in biotech. ALA will help raise Adebiotech's profile and support its growth through public relations activities. Adebiotech leads working groups and conferences on emerging biotech issues involving public and private organizations. The partnership will allow both organizations to increase their visibility and engage with each other's networks in the biotech sector.
1) France's independent multidisciplinary biotechnology think-tank, Adebiotech, promotes interactions between industrial and academic fields to foster sustainable innovations in biotechnology.
2) Adebiotech works across various biotechnology areas like health, environment, food, and industry to create synergies and overcome innovation challenges.
3) Adebiotech's missions include breaking down barriers between disciplines, supporting existing industries, creating new industries, and facilitating dialogue between public and private sectors.
Pherecydes Pharma has launched the Phagoburn clinical trial, the first international clinical study to evaluate the effectiveness of phage therapy in treating serious bacterial infections in burn victims. The randomized, controlled trial will involve 220 patients across 11 hospitals in France, Switzerland, and Belgium. If shown to be safe and effective, phage therapy could provide an alternative or supplement to antibiotics for treating antibiotic-resistant infections.
1) Current in vitro skin safety testing methods have limitations in reliably predicting physiological responses to complex products like natural extracts.
2) Heuristic modelling using CADI can help bridge the gap between in vitro tests and in vivo responses by developing non-linear mechanistic models without assuming functional linearity.
3) CADI models contain elements never described but consistent with current knowledge and can predict experimental modifications, helping validate methods and bypass animal testing.
PharmacoPsychiatry publishes the first invited review describing a productive vision of Systems Medicine that will change R&D organization and interactions between clinicians & researchers.
The invited review explains how the world\'s first explanation of the mechanisms of the Creutzfeldt-Jakob disease led to the discovery of a truly innovative psychiatric treatment
IMPORTANT: If you want to get a clear review of the Differences & Complementarities Between « Heuristic » and « Mathematical » approaches, we invite you to download our presentation given during the EPA (European Psychiatric Association) conference in 2011 that is now utilized in training programs.
About Pherecydes Pharma
Pherecydes Pharma SA specializes in the research and development of lytic bacteriophages
(or phages) for both therapeutic and diagnostic applications. The company provides
innovative and adaptable solutions to combat multi-resistant bacteria, through developing
mixtures of natural phages and their accelerated in vitro evolution. Pherecydes Pharma is
the only company currently that has been able to harness this evolution technology, allowing
a head start on any given bacterium.
Due to the unique knowledge of the company in the characterization and rapid isolation of
natural lytic phages, Pherecydes Pharma has developed a large bank of bacteriophage
mixtures for combating infections that are resistant to antibiotics, which have steadily
increased in number since the 1980s. In particular, it possesses the world’s largest
collection of phages against Escherichia coli and is also working on Pseudomonas and
Staphylococci, three bacteria that alone represent over 50% of known infections in
industrialized countries.
The document summarizes a workshop on applying systems biology approaches to medical research and practice. The workshop aimed to analyze the current state, identify opportunities and barriers, and recommend areas for collaboration. Participants discussed how systems biology could help clinical trials, redefine disease phenotypes, discover biomarkers, enable combinatorial therapies, and improve drug development. Key areas for future research include understanding chronic diseases through network analysis, combining personalized omics data with clinical information, and developing combinatorial drug screening. The major challenge is for systems biology to help transition to a predictive, personalized, preventive and participatory model of medicine.
1. The authors developed technologies to genetically engineer virulent phage banks that could rapidly detect and control emergent pathogenic bacteria.
2. Their approach involves modifying phage genes associated with host range using a technique called TAPE that introduces random mutations while preserving other gene regions, allowing for a wide diversity of variants.
3. They then recombinantly insert the modified genes into the genomes of wild-type phages using a technique called AB-Accus that reversibly interrupts the phage lytic cycle to allow for efficient recombination.
4. This allows production of large phage banks containing variants that could detect and destroy diverse gram-negative bacterial species, providing a flexible means to address emergent outbreaks.
This document discusses proteome-based pathway modelling approaches for understanding psychiatric disorders like schizophrenia and major depressive disorder. It notes that these disorders involve complex interactions between neuronal and non-neuronal (glial) components across different scales. Gene expression data is limited and proteomics approaches using metabolic labelling and mass spectrometry are needed to provide quantitative protein dynamics data. This data can help identify dysfunctional pathways and biomarkers. Modelling approaches are then required to predict molecular and physiological consequences and experimentally test these. Spatially resolved proteomics using techniques like confocal microscopy could help map pathology within affected brain regions.
The DG Research workshop "From Systems Biology to Systems Medicine” report is now available. It is the unique opportunity to discover the 3 best practices and to anticipate the future European Research programs calls
1. BM
Systems
Bio-Modeling Systems
The R&D booster for life sciences discoveries
Short Presentation
The full presentation in available on www.bmsystems.net
Bio-Modeling Systems SAS To contact us
Dr. François Iris (PhD), Chairman & CSO Bio-Modeling Systems SAS
Manuel Gea, Chief Executive Officer 26, rue Saint Lambert
Paul-Henri Lampe CIO Integration Systems Director 75015 PARIS, FRANCE
Dr. Gérard Dine (MD, PhD), Chief Medical Officer e-mail: manuel.gea@bmsystems.net
web site:www.bmsystems.net
BMSYSTEMS 2009
21. BioXplain founders
Three founders sharing same values and history
Company Company specificities Company information
• Created by senior scientists and engineers. • The R&D booster for life sciences
• Inventor of CADI™ methodologies and tools discoveries, Member of BiO
• Research-based biotech company • Established : 2004
• The company does not sell its technologies nor • 9 FTE based in France, 100 people working
access to its technologies on BMSystems research programs
• 1 spin-off Pherecydes-Pharma • Active in the pharma, Industrial biotech,
energy and biosecurity businesses
• Created by senior scientists and biologists. • A State of the Arts software solutions
• Collect, format, store, integrate, analyze and company.
interpret from literature and experimental data • Established 2003.
(“OMICS”, “environmental” data ,…) • 10 people based in Namur Belgium.
• Technology based on a library of powerful • Namur University Spin-off.
software modules that can be easily combined • Numerous clients in the pharma, red and
to create specific custom tools. green biotech industries.
• Created by senior scientists and clinicians • A software provider with strong growth
• Collect, carry and share research, pre-clinical, • Established in 2004.
clinical and post-marketing data using Digital • 40 staff based in France (Gif-sur-Yvette,
Pen and Paper technology, DPP. Grenoble, Reims) and in the United States
• Full, un-biased and complete data capture in (Philadelphia).
real-time ensure the completeness and integrity
of the data. • More than 10 000 users in 44 countries on 5
continents.
28. BioXplain
The Alliance for Integrative Biology
The First Open Platform for Iterative, Predictive and
Integrative Biology
BMSystems enlarges its services proposal to allow the pharmaceutical industry’s scientists and clinicians to harness
existing models using classical “user friendly” & adapted tools to help them work.
Alliance: Co-founder in 2009 of BioXplain, the First Open Platform for Iterative, Predictive and Integrative Biology,
with BioXpr and Kayentis complementary, cutting edge life sciences companies that decided to collaborate to address
this challenge.
BioXplain 2009